Hikal Share Price

    NSE
    345.5
    -1.80 (0.58%)
    HIKAL • 04 Jul, 2025 | 03:29 PM
    BUY

    1Y Annualised Return

    3.03%

    3Y Annualised Return

    14.20%

    5Y Annualised Return

    23.21%

    The current prices are delayed, login or Open Demat Account for live prices.

    Hikal Stock Performance

    1W Return-4.82
    1Y Return2.48
    Today's Low342.8
    Prev. Close347.30
    Mkt Cap (Cr.)4,259.42
    1M Return-8.84
    3Y Return42.25
    52-Week High464.75
    Open347.25
    PE Ratio46.87
    6M Return-12.74
    Today's High349.05
    52-Week Low309.15
    Face Value2

    Hikal Company background

    Founded in: 1988
    Hikal Limited, incorporated on July 8, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division, it offer human health and animal health products.Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C., Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst. During 1996, Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck Co., USA chose Hikal as a partner to outsource Thiabendazole (TBZ, a fungicide). Since the capacity at Mahad was inadequate, Hikal built second greenfield site, a stateoftheart manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new manufacturing facility near Mumbai in collaboration with Merck Co Inc, USA, for the manufacture of a postharvest fungicide. It received the prestigious 5 star Safety Award from British Safety Council UK for high standards maintained at the Taloja Site.During 19992000, the company has acquired an Agrochemical manufacturing site at Panoli, Gujarat from Novartis India Limited. The Companys status as an Export House has been elevated to that of a Trading House. In 2001, it entered the pharmaceuticals business, when it acquired the RD Unit and Bulk Drug Manufacturing Facility of Wintac Ltd at Bangalore in Karnataka. In 2004, it built a brand new API plant postacquisition and received USFDA certification. The Bangalore API Plant approved by USFDA and Australian TGA. During 200405, A 100% EOU plant for pharamaceutical intermediates is being set up. This unit is expected to be operational in the first half of the coming year. During 200405, the company is establishing a stateoftheart RD facility in Pune and this research facility is expected to be operational in early 2006.In Aug. 2004, the company has entered into an agreement with Bayer CropScience AG to manufacture and supply Agro biochemical intermediates and has set up a plant to manufacture this products in Mahad Plant. In 2005, the company made an agreement with Crompton Corporation, USA to manufacture and market a New Generation Crop protection product. In Nov. 2005, the company entered into a JV agreement with a subsidiary company of Sinochem Corporation, China.During 20052006, the company made a strategic investment in Jiangsu Chemstar Industries Co (a subsidiary company of Sinochem Corporation China A Fortune 500 company). The company acquired 10% stake in the year. The companies production capacity of Crop protection products and Pharmaceutical products stood at 4436 MTn and 180 MT respectively. The Company commenced export of Gabapentine to the US and Canada markets during FY 200607. It acquired Marsing Co. A/S, Denmark and commenced marketing and distribution of APIs in various countries. The Company increased investment to 16% in Jiangsu Chemstar Industries Co. Ltd., (a subsidiary company of Sinochem Corporation, China A FORTUNE 500 company) in FY2007. During the year, it started supply of new Crop Protection product to one of the leading multinational companies. In Pharma plant, its existing Intermediate products registered increase in volumes and two new Pharma products were manufactured at Panoli site. RD unit labs got upgraded and two new labs were added during the year 200708.In 2008, the Company established Acoris Research Ltd., a contract research facility at the International Biotech Park, Pune, which is fully operational. In 2009, it expanded manufacturing capabilities. Construction of the new multipurpose active ingredients plant for crop protection at the Taloja site was completed. It commissioned several new multipurpose API plants at the US FDA approved site in Bangalore. It commissioned a new multipurpose pharma intermediates plant at Panoli. Longterm contracts with global life sciences companies had a substantial impact on business. It signed longterm contract for a patented molecule with a leading multinational company.As per the Scheme of Arrangement effective from 1st April 2012, the Research and Development activity of Acoris demerged with Hika. Acoris formerly a subsidiary is now a division of Hikal and further strengthened its capabilities, both in terms of manpower as well as technical capabilities.During the year 2013, it signed a manufacturing agreement with a specialty US based food ingredient company. It completed initial supplies for advanced intermediates to one of the largest U.S. biotech companies. It signed a contract with a leading Japanese company to develop different peptides using their proprietary technology. In December 2016, Company sold its stake in subsidiary, Hikal International B.V. In 2017, it sold the RD unit in Bangalore. The Company issued Bonus Shares on 26 June 2018 in the ratio of 1:2 i.e. one bonus equity share of Rs. 2/ each fully paidup for every two existing equity shares of Rs. 2/ each fully paidup held by the members.In 2023, new product launches in the antidiabetic therapeutic area gained significant traction among global customers. The Company made significant progress on the multiyear Animal Health project with a leading global innovator on developing product portfolio.The new Animal Health MultiPurpose facility commissioned at Panoli, Gujarat in FY 2024.

    As of 04 Jul, 2025, Hikal share price is ₹345.4. The stock opened at ₹347.2 and had closed at ₹347.3 the previous day. During today’s trading session, Hikal share price moved between ₹342.80 and ₹349.05, with an average price for the day of ₹345.93. Over the last 52 weeks, the stock has recorded a low of ₹309.15 and a high of ₹464.75. In terms of performance, Hikal share price has declined by 12.7% over the past six months and has increased by 3.03% over the last year.

    Read More
    Hikal SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years

    Total Investment of ₹65,00,000

    Would have become ₹65,99,855 (+1.54%)

    Daily SIP of 25,000 would have become 65,99,855 in 1 year with a gain of 99,855 (+1.54%)

    View details of Market Depth

    Hikal Fundamental

    Market Cap (in crs)

    4,259.42

    Face Value

    2

    Turnover (in lacs)

    608.13

    Key Metrics

    Qtr Change %
    25.67% Fall from 52W High
    -13.8
    Dividend yield 1yr %
    Below industry Median
    0.3

    Hikal Key Financials

    View more

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    *All values are in ₹ Cr.

    Hikal Quarterly Revenue
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    552.4 Cr
    447.7 Cr
    452.9 Cr
    406.8 Cr
    514.1 Cr
    Hikal Yearly Revenue
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    1864.8 Cr
    1787.05 Cr
    2028.44 Cr
    1947.61 Cr
    1725.42 Cr
    1510.96 Cr
    Hikal Quarterly Net Profit/Loss
    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    50.2 Cr
    17.2 Cr
    18.3 Cr
    5.1 Cr
    33.97 Cr
    Hikal Yearly Net Profit/Loss
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
    90.8 Cr
    69.6 Cr
    78.38 Cr
    160.5 Cr
    133.14 Cr
    84.44 Cr

    Hikal Result Highlights

    • Hikal Ltd reported a 14.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 5.7%.

    • Its expenses for the quarter were up by 9.3% QoQ and down 6.0% YoY.

    • The net profit increased 97.5% QoQ and decreased 5.6% YoY.

    • The earnings per share (EPS) of Hikal Ltd stood at 2.8 during Q4FY25.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Top Mutual Fund Invested in Hikal

    Promoter
    68.8%
    Foreign Institutions
    5.7%
    Mutual Funds
    2.9%
    Domestic Institutions
    3.8%
    Public
    21.6%
    Promoter
    68.8%
    Foreign Institutions
    6.1%
    Mutual Funds
    2.9%
    Domestic Institutions
    3.4%
    Public
    21.6%
    Promoter
    68.8%
    Foreign Institutions
    6.8%
    Mutual Funds
    3.2%
    Domestic Institutions
    3.6%
    Public
    20.8%
    Promoter
    68.8%
    Foreign Institutions
    6.7%
    Mutual Funds
    2.7%
    Domestic Institutions
    3.1%
    Public
    21.3%
    Promoter
    68.8%
    Foreign Institutions
    6.6%
    Mutual Funds
    3%
    Domestic Institutions
    3.5%
    Public
    21.1%
    Promoter
    68.8%
    Foreign Institutions
    6.1%
    Mutual Funds
    2.7%
    Domestic Institutions
    3.2%
    Public
    21.8%

    Hikal Technical Analysis

    Moving Averages Analysis
    345.5
    Current Price
    Bullish Moving Averages
    0
    Bearish Moving Averages
    16
    5Day EMA
    349.30
    10Day EMA
    354.20
    12Day EMA
    355.90
    20Day EMA
    361.60
    26Day EMA
    365.10
    50Day EMA
    373.90
    100Day EMA
    378.10
    200Day EMA
    371.70
    5Day SMA
    348.80
    10Day SMA
    355.70
    20Day SMA
    363.60
    30Day SMA
    367.40
    50Day SMA
    379.30
    100Day SMA
    381.90
    150Day SMA
    382.90
    200Day SMA
    380.40
    Delivery & Volume

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    104410 Rs
    199503 Rs
    Week Rs
    300435 Rs
    505985 Rs
    Month Rs
    152634 Rs
    287477 Rs
    345.77
    Pivot
    Resistance
    First Resistance
    348.73
    Second Resistance
    352.02
    Third Resistance
    354.98
    Support
    First Support
    342.48
    Second support
    339.52
    Third Support
    336.23
    Relative Strength Index
    32.05
    Money Flow Index
    15.28
    MACD
    -9.24
    MACD Signal
    -7.96
    Average True Range
    10.54
    Average Directional Index
    11.02
    Rate of Change (21)
    -7.81
    Rate of Change (125)
    -12.67
    Name
    Holding Percent
    Tata Mutual Fund - Tata Small Cap Fund
    2.68
    Theleme India Master Fund Limited
    1.69
    Government Pension Fund Global
    1.65

    Hikal Latest News

    25 JUN 2025 | Wednesday

    Hikal Ltd - 524735 - Closure of Trading Window

    16 JUN 2025 | Monday

    Hikal Ltd - 524735 - Disclosure Under Regulation 30 SEBI Listing Regulation

    30 MAY 2025 | Friday

    Hikal Ltd - 524735 - Compliances-Reg.24(A)-Annual Secretarial Compliance

    View More

    Hikal Share Price FAQs

    Hikal share price is ₹345.5 in NSE and ₹345 in BSE as on 4/7/2025.

    Hikal share price in the past 1-year return was 2.47. The Hikal share hit a 1-year low of Rs. 309.15 and a 1-year high of Rs. 464.75.

    The market cap of Hikal is Rs. 4259.42 Cr. as of 4/7/2025.

    The PE ratios of Hikal is 46.87 as of 4/7/2025.

    The PB ratios of Hikal is 3.37 as of 4/7/2025

    The Mutual Fund Shareholding in Hikal was 2.93% at the end of 4/7/2025.

    You can easily buy Hikal shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Hikal share price is ₹464.75 and ₹309.15 as of 4/7/2025.

    Please be aware that Hikal stock prices are subject to continuous fluctuations due to various factors.

    Popular Stocks
    65.53
    +0.26 (+0.40%)
    139.24
    -0.46 (-0.33%)
    689.05
    -1.35 (-0.20%)
    2,599.10
    -12.10 (-0.46%)
    166.67
    -0.85 (-0.51%)
    391.40
    +0.75 (+0.19%)
    163.01
    -2.90 (-1.75%)
    261.40
    +0.55 (+0.21%)
    427.55
    +1.30 (+0.30%)
    401.00
    +1.10 (+0.28%)
    Top Gainers
    925.30
    +15.15 (+1.66%)
    1,640.70
    +22.00 (+1.36%)
    1,307.40
    +16.10 (+1.25%)
    1,442.80
    +16.90 (+1.19%)
    270.05
    +3.00 (+1.12%)
    Top Losers
    5,456.00
    -735.00 (-11.87%)
    163.01
    -2.90 (-1.75%)
    5,629.00
    -87.00 (-1.52%)
    1,655.20
    -16.70 (-1.00%)
    12,646.00
    -106.00 (-0.83%)
    Open Demat Account
    +91 -

    Open Demat Account
    +91 -